Fase 2, åbent studie til evaluering af sikkerheden og tolerabiliteten af progerinin i Werners syndrom
Et fase 2, åbent studie for at evaluere sikkerheden og tolerabiliteten af progerinin til behandling af knoglemineraltæthed (BMD) tab hos forsøgspersoner med typisk Werners syndrom
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.
There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.
To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.
The secondary objectives of this study are:
- To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
- To evaluate vascular function in subjects with typical Werner Syndrome.
- To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
- To evaluate lipid metabolism in subjects with typical Werner Syndrome.
- To evaluate physical function in subjects with typical Werner Syndrome.
- To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Christine Lee
- Telefonnummer: 301-540-2600
- E-mail: christinelee@kcrnresearch.com
Studiesteder
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
[Inclusion Criteria]
-
Subjects must be at least ≥ 18 years of age.
-
Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.
-
Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.
-
Male or non-pregnant, non-lactating female.
-
Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.
-
Negative pregnancy test for female subjects as described below. Women of child bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.
Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.
Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.
-
Provide signed written informed consent and willingness, ability to comply with study requirements.
-
Subject must have a projected life expectancy of ≥ 12 months in the opinion of the Investigator.
[Exclusion Criteria]
-
Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:
- Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
- Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
- Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
-
Subjects with significant dehydration as judged by the principal investigator.
-
Subjects with pericardial fluid, ascites and pleural effusion.
-
Therapy with investigational drugs within 30 days of beginning study medication.
-
History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.
-
Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.
-
Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).
-
Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).
-
Subjects with a history of serious drug hypersensitivity or allergic reaction such as anaphylaxis or any component of the formulation.
-
Clinically significant bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).
-
Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.
-
Pregnant or lactating women.
-
Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to baseline or anticipated surgery during the study period.
-
Inability to return for scheduled treatment and assessments.
-
Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Treatment Group
all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year |
This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. . There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
The intensity of the event will be graded using CTCAE v6.0 criteria |
Baseline to Week 56 (including 4-week follow-up)
|
|
Incidence of Treatment-Related Adverse Events
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Incidence of Serious Adverse Events (SAEs)
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Incidence of TEAEs and SAEs leading to discontinuation of study medication
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Blood Chemistry from Baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Hematology from Baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Urinalysis Results from Baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Height (cm) from Baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Weight (kg) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Temperature (°C) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Pulse Rate (beats per minute) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Respiratory Rate (breaths per minute) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Systolic Blood pressure (mmHg) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Diastolic Blood pressure (mmHg) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Physical Examination findings from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG Ventricular Rate (beats per minute) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG PR interval (msec) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QRS interval (msec) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QT interval (msec) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QTc interval (msec) from baseline
Tidsramme: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in Femur Bone Mineral Density (BMD) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Lumbar Spine BMD from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Aortic Pulse Wave Velocity (m/s) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Lipid Profile from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Handgrip Strength Test from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Short Physical Performance Battery (SPPB) Total Score from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Ankle-Brachial Pressure Index (ABPI) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Osteocalcin (OC) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Procollagen Peptides (P1NP) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Deoxypyridinium (DPD) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline
Tidsramme: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits
Tidsramme: Baseline, Week12, Week 24, Week 36 and Week 52
|
Baseline, Week12, Week 24, Week 36 and Week 52
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PRG-PRO-004
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .